Table 1 Brief summary of the potential molecular targets for optimized anti-angiogenesis therapy
Project | Potential molecular targets | Related process | Tumor types/cell lines | method | PMID |
|---|---|---|---|---|---|
Signaling pathway | |||||
TGFβ Signaling pathway | TGFβ | EMT-embryonic phenotype regain; | U251 | Transfection and RNAi | 22104964 |
tumor microenvironment remodulation | SHG44 | 24370825 | |||
VEGFR-2/Flk-1 pathway | VEGFR-2 | Self-renewal, tumorigenicity and tubular formation | U87 derived GSCs, | Transfection and RNAi; | 23536763 |
GBM samples | Immunohistochemistry, | ||||
| Â | Xenograft models | ||||
U87 | RNAi; | 22654102 | |||
GSDC | xenotransplantation | ||||
VE-cadherin/CDH5 and EphA2 pathways | VE-cadherin | hypoxia induced microenvironment remodulation; | Glioma samples;GSCs | RT-PCR, western blot, immunohistochemistry; | 23645533 |
RNAi and xenograft models | |||||
EphA2 and MiR-26b | Cell proliferation, invasion and tubular formation | Glioma samples; | RT-PCR; | 21264258 | |
U251 and C6 | Transfection and RNAi | ||||
RTK/PI3K/Akt/mTOR pathway | RTK/PI3K/mTOR | Cell proliferation, apoptosis, microenvironment remodulation. | U251 and T98G | Pharmacologic inhibitor, RNAi | 24418474 |
MMP-laminin5γ2 chain pathway | MMPs | a shared downstream signaling pathway | U251 | Transfection and RNAi | 22104964 |
SHG44 | |||||
others | COX-2 | Promote cell survival, proliferation, and angiogenesis and prohibit apoptosis | Glioma specimen | Immunohistochemistry, Kaplan–Meier survival analysis and log-rank tests | 21533525 |
MiR-9 | Cell proliferation and apoptosis | U87MG | Transfection and RNAi | 24043603 | |
U251 | |||||
SHG44 |